Found 205 Type 2 Diabetes Mellitus trials
A listing of Type 2 Diabetes Mellitus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
In this study, the Investigators at the University of Pennsylvania will assess organ-specific biomarker profiles (proteins and metabolites), in order to better understand biologic processes, the interplay between the heart and extracardiac organs, and their role in human disease, with an emphasis on cardiovascular disease. The study will specifically focus …
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in multiple myeloma patients.
This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in patients with lupus nephritis (LN) in the U.S. This registry is intended to benefit and support interests of patients, clinicians, regulatory bodies, payers, and industry by obtaining longitudinal data on LUPKYNIS.
The purpose of the study is to define the safety and tolerability of ascending doses of VB119 in subjects with primary membranous nephropathy. Study drug will be administered intravenously. The Data Review Committee will review safety data and determine dosage based on available safety, PD and other clinical data. Participants …
This trial explores the efficacy of 3 doses (20 mg, 40 mg, and 80 mg) of BI 764198 with respect to their benefit to lower proteinuria, and investigates the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of BI 764198 vs placebo.
This trial seeks to evaluates the efficacy, safety, and tolerability of ianalumab, compared to placebo, in achieving stable complete renal response at week 72 in adults with active lupus nephritis on background SoC therapy.
Study is enrolling IgAN patients who continue to have persistent proteinuria despite being on RAAS inhibitors for at least 12 weeks. The study intervention is subcutaneous atacicept given once a week. Interested subjects will be taking study drug for up to 96 weeks (36 weeks blinded + 60 weeks open …
The purpose of this study is to evaluate the safety and efficacy of atrasentan vs placebo while on background therapy with SGLT2i in subjects with IgAN. The primary efficacy assessment is the change from baseline in proteinuria at week 12. Individual subject participation duration: up to 64 weeks for subjects …
Study is enrolling patients with IgAN (IgA Nephropathy) to find out if oral atrasentan will delay worsening of kidney functions in comparison to placebo. Subjects will be asked to complete questionnaires, do a physical exam, perform ECG, give blood and urine samples, and weigh themselves.
This is not a research study. We are not sharing any information for analyses. The device is FDA approved. IRB approval is required for device manufacturer to allow us to move forward with using therapy at Penn.
